CoChat

Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis

Open access
Pingitore, Piero, Sasidharan, Kavitha, Ekstrand, Matias, Prill, Sebastian, Lindén, Daniel, Romeo, Stefano · 2019 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in western countries. Despite the high prevalence of NAFLD, the underlying biology of the disease progression is not clear, and there are no approved drugs to treat non-alcoholic steatohepatitis (NASH), the most advanced form of the disease. Thus, there is an urgent need for developing advanced in vitro human cellular systems to study disease mechanisms and drug responses. We attempted to create an organoid system genetically predisposed to NAFLD and to induce steatosis and fibrosis in it by adding free fatty acids. We used multilineage 3D spheroids composed by hepatocytes (HepG2) and hepatic stellate cells (LX-2) with a physiological ratio (24:1). HepG2 and LX-2 cells are homozygotes for the PNPLA3 I148M sequence variant, the strongest genetic determinant of NAFLD. We demonstrate that hepatic stellate cells facilitate the compactness of 3D spheroids. Then, we show that the spheroids develop accumulations of fat and collagen upon exposure to free fatty acids. Finally, this accumulation was rescued by incubating spheroids with liraglutide or elafibranor, drugs that are in clinical trials for the treatment of NASH. In conclusion, we have established a simple, easy to handle, in vitro model of genetically induced NAFLD consisting of multilineage 3D spheroids. This tool may be used to understand molecular mechanisms involved in the early stages of fibrogenesis induced by lipid accumulation. Moreover, it may be used to identify new compounds to treat NASH using high-throughput drug screening.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms20071629

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Co-culture of HepG2 and LX-2 cells enhances the compactness of 3D spheroids. (A) HepG2 cells, which formed loosely aggregated spheroids alone, were co-cultured as multilineage spheroids with LX-2 cells (forming round-shape spheroids quickly) at a 1:1 and 24:1 ratio for 24, 48, 72 and 96 h. Scale bars in bright-field pictures are 100 μm. (B) Spheroid volume was calculated measuring their long and short diameter by ZEN 2.3 Lite software (Zeiss) (n = 4). (C) Cellular ATP levels normalized to spheroids volumes remained stable throughout 4 days of culture (n = 3). (D) Apolipoprotein B (APOB) secretion levels in the media fractions measured by Western blotting are proportioned to the percentage of hepatocytes present in the spheroids (n = 5). Bars represent mean ± SD. P-values were calculated by Mann-Whitney non-parametric test, (* p < 0.05 vs. HepG2). APOB: Apolipoprotein B; AU: arbitrary unit.
Figure 1 Co-culture of HepG2 and LX-2 cells enhances the compactness of 3D spheroids. (A) HepG2 cells, which formed loosely aggregated spheroids alone, were co-cultured as multilineage spheroids with LX-2 cells (forming round-shape spheroids quickly) at a 1:1 and 24:1 ratio for 24, 48, 72 and 96 h. Scale bars in bright-field pictures are 100 μm. (B) Spheroid volume was calculated measuring their long and short diameter by ZEN 2.3 Lite software (Zeiss) (n = 4). (C) Cellular ATP levels normalized to spheroids volumes remained stable throughout 4 days of culture (n = 3). (D) Apolipoprotein B (APOB) secretion levels in the media fractions measured by Western blotting are proportioned to the percentage of hepatocytes present in the spheroids (n = 5). Bars represent mean ± SD. P-values were calculated by Mann-Whitney non-parametric test, (* p < 0.05 vs. HepG2). APOB: Apolipoprotein B; AU: arbitrary unit.CC BY · PubMed Central
Figure 2 Treatments of organoid with fatty acids do not change organoid volume and viability but enhance APOB secretion. (A) 3D spheroids HepG2/LX-2 ratio 24:1 were treated, after 48 h from the seeding with: BSA 1%, a mix of palmitic acid and oleic acid 500 μM (1:2), TGF-β 10 ng/mL or PDGF 10 ng/mL for 24 or 48 h. (B) Spheroid volumes were calculated measuring their long and short diameter by ZEN 2.3 Lite software (Zeiss) (n = 3). (C) Cellular ATP levels normalized to spheroids volumes remained stable throughout 4 days of culture (n = 3). (D) APOB secretion levels in the media fractions measured by Western blotting were higher in spheroids treated with PAOA while they were lower in spheroids treated with TGF-β (n = 7). Bars represent mean ± SD. P-value was calculated by Mann-Whitney non-parametric test, (* p < 0.05 vs. BSA 1%). BSA: bovine serum albumin; PAOA: palmitic acid/oleic acid; TGF-β: Transforming growth factor-β; PDGF: Platelet-derived growth factor; APOB: Apolipoprotein B; AU: arbitrary unit.
Figure 2 Treatments of organoid with fatty acids do not change organoid volume and viability but enhance APOB secretion. (A) 3D spheroids HepG2/LX-2 ratio 24:1 were treated, after 48 h from the seeding with: BSA 1%, a mix of palmitic acid and oleic acid 500 μM (1:2), TGF-β 10 ng/mL or PDGF 10 ng/mL for 24 or 48 h. (B) Spheroid volumes were calculated measuring their long and short diameter by ZEN 2.3 Lite software (Zeiss) (n = 3). (C) Cellular ATP levels normalized to spheroids volumes remained stable throughout 4 days of culture (n = 3). (D) APOB secretion levels in the media fractions measured by Western blotting were higher in spheroids treated with PAOA while they were lower in spheroids treated with TGF-β (n = 7). Bars represent mean ± SD. P-value was calculated by Mann-Whitney non-parametric test, (* p < 0.05 vs. BSA 1%). BSA: bovine serum albumin; PAOA: palmitic acid/oleic acid; TGF-β: Transforming growth factor-β; PDGF: Platelet-derived growth factor; APOB: Apolipoprotein B; AU: arbitrary unit.CC BY · PubMed Central
Figure 3 Treatment with fatty acids (PAOA) increases neutral fat content in 3D multilineage spheroids. (A) Intracellular neutral lipid content visualized by ORO staining in sections (8 μm) of 3D spheroids HepG2/LX-2 ratio 24:1 treated, after 48 h from the seeding with BSA 1%, a mix of palmitic acid and oleic acid (PAOA) 500 μM (1:2), TGF-β 10 ng/mL or PDGF 10 ng/mL for 48 h. Cell nuclei were stained with hematoxylin. Objective: 40×. (B) Quantification of intracellular ORO-stained area quantified by BioPix software (n = 5). (C) Intracellular lipid content measured by AdipoRed assay kit (Lonza). Bars represent mean ± SD (n = 6). P-value was calculated by Mann-Whitney non-parametric test, (** p < 0.005 vs. BSA 1%). BSA: bovine serum albumin; PAOA: palmitic acid/oleic acid; TGF-β: Transforming growth factor β; PDGF: Platelet-derived growth factor, ORO: oil red O staining.
Figure 3 Treatment with fatty acids (PAOA) increases neutral fat content in 3D multilineage spheroids. (A) Intracellular neutral lipid content visualized by ORO staining in sections (8 μm) of 3D spheroids HepG2/LX-2 ratio 24:1 treated, after 48 h from the seeding with BSA 1%, a mix of palmitic acid and oleic acid (PAOA) 500 μM (1:2), TGF-β 10 ng/mL or PDGF 10 ng/mL for 48 h. Cell nuclei were stained with hematoxylin. Objective: 40×. (B) Quantification of intracellular ORO-stained area quantified by BioPix software (n = 5). (C) Intracellular lipid content measured by AdipoRed assay kit (Lonza). Bars represent mean ± SD (n = 6). P-value was calculated by Mann-Whitney non-parametric test, (** p < 0.005 vs. BSA 1%). BSA: bovine serum albumin; PAOA: palmitic acid/oleic acid; TGF-β: Transforming growth factor β; PDGF: Platelet-derived growth factor, ORO: oil red O staining.CC BY · PubMed Central
Figure 4 Fatty acid treatment results in an increase in COL1A1 levels in 3D multilineage spheroids. (A) Immunofluorescence staining of DAPI (blue), COL1A1 (red) and merged images of 3D spheroids (HepG2/LX-2, 24:1) treated, after 48 h from the seeding, with BSA 1% (negative control), a mix of palmitic acid and oleic acid 500 μM (1:2), TGF-β 10 ng/mL or PDGF 10 ng/mL for 48 h. All the media for treatments were supplemented with BSA 1%. Objective: 40×. (B) Quantification of COL1A1 levels by ImageJ normalized to number of nuclei. Bars represent mean ± SD (n = 6). P-value was calculated by Mann Whitney non-parametric test, (** p < 0.005 vs. BSA 1%). BSA: bovine serum albumin; PAOA: palmitic acid/oleic acid; TGF-β: Transforming growth factor β; PDGF: Platelet-derived growth factor. COL1A1: collagen type I alpha 1.
Figure 4 Fatty acid treatment results in an increase in COL1A1 levels in 3D multilineage spheroids. (A) Immunofluorescence staining of DAPI (blue), COL1A1 (red) and merged images of 3D spheroids (HepG2/LX-2, 24:1) treated, after 48 h from the seeding, with BSA 1% (negative control), a mix of palmitic acid and oleic acid 500 μM (1:2), TGF-β 10 ng/mL or PDGF 10 ng/mL for 48 h. All the media for treatments were supplemented with BSA 1%. Objective: 40×. (B) Quantification of COL1A1 levels by ImageJ normalized to number of nuclei. Bars represent mean ± SD (n = 6). P-value was calculated by Mann Whitney non-parametric test, (** p < 0.005 vs. BSA 1%). BSA: bovine serum albumin; PAOA: palmitic acid/oleic acid; TGF-β: Transforming growth factor β; PDGF: Platelet-derived growth factor. COL1A1: collagen type I alpha 1.CC BY · PubMed Central
Figure 5 Incubation of 3D multilineage spheroids with liraglutide or elafibranor results in a reduction of intra-spheroid fat content. Prevention of steatosis by co-treatment with (A) Liraglutide (1, 10 and 20 μM), (B) Elafibranor (10, 25, 50 μM), (C) vitamin E (10, 25, 50 μM) or (D) obeticholic acid (10, 25, 50 μM) for 48 h in the presence of 500 μM free fatty acids (PAOA) bound to BSA 1%. On the left panels, lipid levels were quantified using AdipoRed biochemical quantification assay. On the right panels cellular ATP levels, normalized to spheroids volumes, remained stable throughout 48 h of treatment (n = 3). Bars represent mean ± SD. P-value was calculated by Mann-Whitney non-parametric test, (* p < 0.05 vs. PAOA 500 μM; # p < 0.005 vs. BSA 1%). BSA: bovine serum albumin; PAOA: palmitic acid/oleic acid.
Figure 5 Incubation of 3D multilineage spheroids with liraglutide or elafibranor results in a reduction of intra-spheroid fat content. Prevention of steatosis by co-treatment with (A) Liraglutide (1, 10 and 20 μM), (B) Elafibranor (10, 25, 50 μM), (C) vitamin E (10, 25, 50 μM) or (D) obeticholic acid (10, 25, 50 μM) for 48 h in the presence of 500 μM free fatty acids (PAOA) bound to BSA 1%. On the left panels, lipid levels were quantified using AdipoRed biochemical quantification assay. On the right panels cellular ATP levels, normalized to spheroids volumes, remained stable throughout 48 h of treatment (n = 3). Bars represent mean ± SD. P-value was calculated by Mann-Whitney non-parametric test, (* p < 0.05 vs. PAOA 500 μM; # p < 0.005 vs. BSA 1%). BSA: bovine serum albumin; PAOA: palmitic acid/oleic acid.CC BY · PubMed Central
Figure 6 COL1A1 levels decrease in 3D multilineage spheroids treated with liraglutide or elafibranor. (A) Immunofluorescence staining of DAPI (blue), COL1A1 (red), and merged images of 3D spheroids (HepG2/LX-2, 24:1) treated, after 48 h from the seeding, with a mix of palmitic acid and oleic acid 500 μM (1:2) bound to BSA 1%, with and without liraglutide 20 μM, elafibranor 50 μM, vitamin E 50 μM or obeticholic acid 50 μM for 48 h. Objective: 40×. (B) Quantification of COL1A1 levels by ImageJ normalized to number of nuclei. Bars represent mean ± SD (n = 4). P-value was calculated by Mann Whitney test non-parametric test, (* p < 0.05 vs. PAOA 500 μM). PAOA: palmitic acid/oleic acid; COL1A1: collagen type I alpha 1.
Figure 6 COL1A1 levels decrease in 3D multilineage spheroids treated with liraglutide or elafibranor. (A) Immunofluorescence staining of DAPI (blue), COL1A1 (red), and merged images of 3D spheroids (HepG2/LX-2, 24:1) treated, after 48 h from the seeding, with a mix of palmitic acid and oleic acid 500 μM (1:2) bound to BSA 1%, with and without liraglutide 20 μM, elafibranor 50 μM, vitamin E 50 μM or obeticholic acid 50 μM for 48 h. Objective: 40×. (B) Quantification of COL1A1 levels by ImageJ normalized to number of nuclei. Bars represent mean ± SD (n = 4). P-value was calculated by Mann Whitney test non-parametric test, (* p < 0.05 vs. PAOA 500 μM). PAOA: palmitic acid/oleic acid; COL1A1: collagen type I alpha 1.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Cited by

See all 157

Metadata

Authors
Pingitore, P., Sasidharan, K., Ekstrand, M., Prill, S., Lindén, D., & Romeo, S.
Affiliations
  • University of Gothenburg (SE)
  • AstraZeneca (Sweden) (SE)
  • Sahlgrenska University Hospital (SE)
Corresponding author
Romeo, Stefano
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2019-04-02
Volume
20
Issue
7
Pages
1629
ISSN
1422-0067 (ISSN-L)
OpenAlex
W2935565749
Cited by
152
References
64
Citations by year
2026: 28 · 2025: 22 · 2024: 19 · 2023: 23 · 2022: 22 · 2021: 16 · 2020: 19 · 2019: 2
FWCI
11.22
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Vetenskapsrådet (2016-01527)
  • Hjärt-Lungfonden (20120533)
  • the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (SU 2018-04276)
  • Novonordisk Foundation Grant for Excellence in Endocrinology (Excellence Project, 9321-430)
  • Swedish Diabetes Foundation (DIA 2017-205)
  • Research grant from AstraZeneca (Echo Project, 10033852)
  • Wallenberg Academy Fellows from the Knut and Alice Wallenberg Foundation (KAW 2017.0203)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, hepatic steatosis, liver fibrosis, multicellular spheroids, organoids, PNPLA3 I148M, HepG2 cells, LX-2 cells, hepatic stellate cells, hepatocytes, free fatty acids, liraglutide, elafibranor, in vitro disease model, drug screening
MeSH terms
Liraglutide, Apolipoproteins B, Fatty Acids, Humans, Liver Cirrhosis, Models, Biological, Propionates, Spheroids, Cellular, Coculture Techniques, Cell Lineage, Collagen Type I, Chalcones, Hep G2 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis. https://app.cochat.ai/papers/10.3390/ijms20071629
The paper
Pingitore, P., Sasidharan, K., Ekstrand, M., Prill, S., Lindén, D., & Romeo, S. (2019). Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms20071629

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.